Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Sarepta Therapeutics ( (SRPT)) just unveiled an update. On December 10, 2025, Sarepta Therapeutics, Inc. entered into privately negotiated exchange agreements with certain holders of its 1.25% ...

Sarepta Therapeutics is upgraded to a buy following HHS's addition of Duchenne muscular dystrophy to the newborn screening panel. Earlier DMD detection aligns perfectly with SRPT's preventative ...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Dec. 31, 2025 that were previously ...